Pelthos Therapeutics to merge with Castle Creek in DEB cell therapy deal
Pelthos Therapeutics (NYSE American: PTHS) has signed a definitive agreement to merge with Castle Creek Biosciences, combining the latter's late-stage fibroblast-based cell and gene therapy platform with Pelthos' three FDA-approved dermatology products. The combined entity will retain the Pelthos Therapeutics name and continue to trade on NYSE American under the ticker PTHS.
The deal centres on Castle Creek's lead candidate, D-Fi (dabocemagene autoficel; FCX-007), an autologous gene-modified cell therapy in development for dystrophic epidermolysis bullosa (DEB). DEB is a rare, inherited blistering disorder caused by mutations in the COL7A1 gene, which normally encodes type VII collagen, a structural protein essential to skin integrity. D-Fi delivers the patient's own fibroblasts, modified ex vivo using a lentiviral vector carrying the corrected COL7A1 gene, via intradermal injection at wound sites every other month. The candidate holds Orphan Drug, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA.
Deal terms and milestones
Under the agreement, Castle Creek shareholders will receive 5.2 million shares of Pelthos common stock at closing, representing roughly 32.5% of fully diluted shares. A further 5.8 million shares become available upon FDA approval of D-Fi. Beyond equity, the structure includes up to $300 million in milestone payments: $50 million linked to specified Phase 3 clinical endpoints, and up to $250 million tied to first commercial sale and subsequent net sales thresholds. Castle Creek shareholders will also receive 80% of any priority review voucher proceeds awarded upon D-Fi's FDA approval. The transaction, approved by both boards, is expected to close by the end of the first quarter of 2027, subject to Castle Creek stockholder approval and customary closing conditions. Scott Plesha will continue as chief executive, with Peter Greenleaf joining as executive chair.
Pelthos chief executive Scott Plesha said the combination "broadens our focus beyond cutaneous infectious diseases to serious diseases that affect the skin" and that the company's existing paediatric dermatology relationships would help accelerate D-Fi's commercial launch. Castle Creek chairman and chief executive Matt Gantz described D-Fi as having "the potential to become a blockbuster franchise in DEB."
Market context and competitive landscape
DEB affects an estimated one in 200,000 individuals in the US and Europe, with recessive DEB being the more severe and prevalent subtype. The condition carries a markedly elevated lifetime risk of squamous cell carcinoma, and wound management consumes significant healthcare resources. Only one other gene therapy product for a genetic skin disorder has reached late-stage development in recent years, and the broader DEB treatment landscape remains thin, giving Castle Creek's redosable approach a meaningful point of differentiation if Phase 3 data prove out.
The cell and gene therapy sector has experienced a capital-intensive period, with several autologous programmes running into manufacturing cost and scalability headwinds. Pelthos' existing commercial infrastructure in dermatology is positioned by the company as a solution to that launch-readiness problem, though investors will note that Pelthos' own revenue base is built on topical small-molecule products serving very different patient populations. The PRV mechanism adds a potentially significant financial lever: rare paediatric disease vouchers have traded at between $100 million and $150 million in recent years, meaning the 80% share allocated to Castle Creek stockholders could represent material additional value if D-Fi reaches approval.
The transaction is expected to sharpen scrutiny of Phase 3 design and enrolment timelines. A $50 million milestone payment tied to Phase 3 clinical endpoints aligns the financial incentives of both parties closely with trial execution.